Abbott Laboratories (NYSE:ABT) – Equities researchers at Gabelli increased their FY2018 earnings per share estimates for shares of Abbott Laboratories in a report released on Friday. Gabelli analyst J. Tsai now forecasts that the healthcare product maker will earn $2.75 per share for the year, up from their prior estimate of $2.70. Gabelli also issued estimates for Abbott Laboratories’ FY2019 earnings at $3.05 EPS, FY2020 earnings at $3.40 EPS and FY2021 earnings at $3.75 EPS.

A number of other brokerages also recently weighed in on ABT. UBS AG reiterated a “neutral” rating and issued a $41.00 target price on shares of Abbott Laboratories in a report on Tuesday, April 18th. BMO Capital Markets reiterated a “hold” rating and issued a $48.00 target price on shares of Abbott Laboratories in a report on Tuesday, July 11th. Stifel Nicolaus reiterated a “buy” rating and issued a $58.00 target price on shares of Abbott Laboratories in a report on Friday. Barclays PLC reiterated an “overweight” rating and issued a $57.00 target price (up previously from $52.00) on shares of Abbott Laboratories in a report on Saturday. Finally, Guggenheim began coverage on Abbott Laboratories in a report on Thursday, June 29th. They issued a “buy” rating and a $58.00 price objective on the stock. Four equities research analysts have rated the stock with a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the stock. Abbott Laboratories has a consensus rating of “Buy” and a consensus target price of $52.13.

TRADEMARK VIOLATION NOTICE: This article was published by American Banking News and is the property of of American Banking News. If you are accessing this article on another site, it was illegally copied and republished in violation of US & international copyright & trademark legislation. The original version of this article can be viewed at https://www.americanbankingnews.com/2017/07/24/fy2018-earnings-estimate-for-abbott-laboratories-abt-issued-by-gabelli.html.

Shares of Abbott Laboratories (ABT) opened at 50.84 on Monday. The stock has a market capitalization of $88.22 billion, a P/E ratio of 71.20 and a beta of 1.06. Abbott Laboratories has a one year low of $37.38 and a one year high of $51.13. The stock’s 50 day moving average is $48.18 and its 200-day moving average is $44.68.

Abbott Laboratories (NYSE:ABT) last announced its earnings results on Thursday, July 20th. The healthcare product maker reported $0.62 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.60 by $0.02. The company had revenue of $6.64 billion during the quarter, compared to analysts’ expectations of $6.63 billion. Abbott Laboratories had a net margin of 4.96% and a return on equity of 15.53%. The firm’s quarterly revenue was up 24.5% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.55 earnings per share.

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, August 15th. Stockholders of record on Friday, July 14th will be issued a dividend of $0.265 per share. This represents a $1.06 annualized dividend and a dividend yield of 2.08%. The ex-dividend date of this dividend is Wednesday, July 12th. Abbott Laboratories’s dividend payout ratio (DPR) is presently 149.30%.

In other Abbott Laboratories news, insider Jared Watkin sold 552 shares of the business’s stock in a transaction that occurred on Thursday, June 15th. The stock was sold at an average price of $47.97, for a total value of $26,479.44. Following the sale, the insider now owns 47,090 shares in the company, valued at approximately $2,258,907.30. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Joseph J. Manning sold 4,200 shares of the business’s stock in a transaction that occurred on Wednesday, April 26th. The shares were sold at an average price of $43.95, for a total value of $184,590.00. Following the completion of the sale, the insider now owns 26,224 shares in the company, valued at approximately $1,152,544.80. The disclosure for this sale can be found here. Insiders have sold a total of 206,902 shares of company stock worth $9,497,761 in the last quarter. 0.76% of the stock is currently owned by company insiders.

Large investors have recently added to or reduced their stakes in the stock. Boothbay Fund Management LLC bought a new position in Abbott Laboratories during the fourth quarter valued at $348,000. Cigna Investments Inc. New bought a new position in Abbott Laboratories during the fourth quarter valued at $2,084,000. L & S Advisors Inc bought a new position in Abbott Laboratories during the fourth quarter valued at $468,000. Menora Mivtachim Holdings LTD. bought a new position in Abbott Laboratories during the fourth quarter valued at $129,000. Finally, Congress Asset Management Co. MA bought a new position in Abbott Laboratories during the fourth quarter valued at $348,000. Hedge funds and other institutional investors own 71.08% of the company’s stock.

Abbott Laboratories Company Profile

Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States.

Earnings History and Estimates for Abbott Laboratories (NYSE:ABT)

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.